Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer

Abstract

Gastric cancer (GC) is a malignant tumor with high incidence rate and mortality. Due to the lack of effective diagnostic indicators, most patients are diagnosed in late stage and have a poor prognosis. An increasing number of studies have proved that Peptidylprolyl isomerase A (PPIA) can play an oncogene role in various cancer types. However, the precise mechanism of PPIA in GC is still unclear. Herein, we analyzed the mRNA levels of PPIA in pan-cancer. The prognostic value of PPIA on GC was also evaluated using multiple databases. Additionally, the relationship between PPIA expression and clinical factors in GC was also examined. We further confirmed that PPIA expression was not affected by genetic alteration and DNA methylation. Moreover, the upstream regulator miRNA and lncRNA of PPIA were identified, which suggested that LINC10232/miRNA-204-5p/PPIA axis might act as a potential biological pathway in GC. Finally, this study revealed that PPIA was negatively correlated with immune checkpoint expression, immune cell biomarkers, and immune cell infiltration in GC.

Decoding the molecular landscape: A novel prognostic signature for uveal melanoma unveiled through programmed cell death-associated genes

“…[26,27] Aberrant expression of PPIA, GUSB, and CEACAM5 has also been observed in certain cancers and may be associated with tumor progression and potential tumor markers. [28][29][30][31][32] Additionally, ACP5, encoding acid phosphatase prostate, is involved in bone metabolism, and its dysregulation may be related to bone metastasis. [33] Given the known roles of these genes in cancer, further investigation into their functions and mechanisms in UM is warranted.…”